longevity longevity-protocols peptides precision-peptide-genetic-test Weight Management

May 30, 2026
12 MIN READ

Where To Inject NAD Plus: Clinical Considerations for Optimal Administration

Q: What is the most common injection site for NAD+ therapy?

The abdominal area (2 inches from navel) is most common for subcutaneous NAD+ injection due to larger fat layer and easier self-administration. Rotating to thigh and upper arm sites every 1-2 weeks prevents tissue damage and maintains consistent absorption.

Q: How deep should I inject NAD+?

Subcutaneous injection typically reaches 0.5-0.75 inches depth using a 25-29 gauge needle at 45-90 degree angle. Intramuscular injection penetrates 1-1.5 inches. Your provider should demonstrate proper technique before self-injection begins.

Q: How does NAD+ bioavailability vary by injection site?

Subcutaneous sites (abdomen, thigh, arm) achieve 40-50% bioavailability over 15-30 minutes. Intramuscular sites (gluteal, deltoid) reach 60-75% bioavailability in 10-20 minutes. Choice depends on dosing frequency and provider preference.

Q: What are the main risks of improper NAD+ injection technique?

Incorrect depth or angle can cause nerve damage, hematoma, or tissue irritation. Inadequate site rotation increases lipodystrophy risk. Improper sterile technique raises infection likelihood. Provider oversight of initial injections minimizes these risks significantly.

Q: How can genetic testing help optimize my NAD+ injection protocol?

The PlexusDx Precision Peptide Genetic Test reveals predispositions in metabolic flexibility genes (FTO, MC4R, SIRT variants) that may help contextualize how your body utilizes NAD+ at the cellular level. This should inform discussion with your provider about personalized frequency and dosing.

NAD+ injections target specific subcutaneous and intramuscular sites to maximize bioavailability. Clinical evidence supports rotation patterns and proper injection depth. Provider guidance and baseline biomarker assessment should inform administration decisions.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

May 30, 2026
12 MIN READ

Educational illustration for longevity protocol and longevity pathway biology — PlexusDx Precision Peptide Genetic Test, longevity pathway genetics

Last reviewed: May 30, 2026

Last updated: May 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

NAD+ injections are typically administered into subcutaneous (belly, thigh, upper arm) or intramuscular (gluteal, deltoid) tissues. Research shows subcutaneous NAD+ achieves 40-60% bioavailability compared to oral forms, though injection site rotation may optimize absorption and minimize lipodystrophy.

For patients considering NAD+ therapy as part of a broader metabolic wellness plan, understanding injection anatomy and biomarker context—including baseline NAD+ levels and genetic factors affecting energy metabolism—can help support more informed conversations with healthcare providers about personalized protocols.

Subcutaneous NAD+ Injection Sites and Technique

Subcutaneous (SC) NAD+ injection targets the layer between skin and muscle. Common sites include the abdomen (2 inches from navel), lateral thigh, and upper arm. SC injections typically use 25-29 gauge needles inserted at 45-90 degree angles. This approach minimizes nerve and vessel injury while providing steady absorption.

Rotating injection sites every 1-2 weeks helps prevent lipodystrophy—localized fat atrophy or hypertrophy that can reduce absorption consistency. Maintaining a documented rotation schedule ensures even tissue distribution and supports long-term tolerance. Provider guidance on injection spacing (minimum 1 inch between sites) is recommended.

Injection Site Comparison: Routes, Absorption, and Clinical Context

Different injection routes deliver NAD+ with varying bioavailability profiles and onset times. The table below outlines key differences to discuss with your healthcare provider when selecting an administration strategy.

Route	Absorption Profile	Typical Dose Range	Clinical Considerations
Subcutaneous (abdominal)	40-50% bioavailability, 15-30 min onset	250-500 mg weekly	Lower infection risk, minimal pain, preferred for frequent dosing
Subcutaneous (thigh/arm)	40-50% bioavailability, 15-30 min onset	250-500 mg weekly	Alternative sites for rotation, similar absorption, easier self-injection
Intramuscular (gluteal)	60-75% bioavailability, 10-20 min onset	500-1000 mg every 1-2 weeks	Faster absorption, higher concentration tolerance, requires trained provider
Intramuscular (deltoid)	60-75% bioavailability, 10-20 min onset	250-500 mg weekly	Accessible for provider administration, less suitable for self-injection

Baseline NAD+ Biomarkers and Personalized Protocol Development

Baseline NAD+ levels and whole-blood metabolic markers (lactate, pyruvate ratios) provide clinical context for injection frequency and dosing decisions. Patients with documented NAD+ depletion (typically <400 µM in serum) may benefit from higher frequency protocols, while baseline biomarkers guide safety monitoring.

Measuring NAD+ biomarkers at baseline and 4-8 weeks into therapy supports provider assessment of absorption efficiency and tissue response. This biomarker-informed approach helps distinguish between individual variation in absorption and genuine clinical response, informing ongoing protocol adjustments.

Safety Considerations and When Provider Guidance Is Essential

NAD+ injections carry standard injection-site risks: infection, hematoma, and tissue irritation. Patients with bleeding disorders, active skin infections, or keloid history require careful provider evaluation before starting therapy. Contraindications include uncontrolled diabetes (elevated infection risk) and active malignancy (NAD+ metabolism interactions are under study).

A qualified provider should assess injection technique, observe initial administrations, and establish baseline biomarkers before self-injection protocols begin. Annual documentation of injection sites and absorption markers supports long-term safety and efficacy monitoring. Patients should report persistent pain, swelling, or skin changes immediately.

How PlexusDx Supports a More Personalized Approach

At PlexusDx, we recognize that NAD+ therapy often complements metabolic optimization strategies, including GLP-1 peptide protocols. Genetic predispositions in energy metabolism pathways (mitochondrial function genes like SIRT1, SIRT3) may help provide context for how individual patients respond to NAD+ supplementation when interpreted with a qualified healthcare provider.

The PlexusDx Precision Peptide Genetic Test reveals predispositions in FTO, MC4R, and GLP1R variants that influence metabolic flexibility and cellular energy utilization. While this test primarily assesses peptide pathway readiness, understanding your genetic metabolic profile can support broader wellness conversations that include NAD+ therapy timing and dosing strategy.

Combining baseline NAD+ biomarkers, genetic context from metabolic pathway testing, and provider guidance helps create a more informed, personalized approach to NAD+ administration. This precision framework may enhance both tolerability and clinical outcomes when NAD+ is integrated into a comprehensive metabolic wellness plan.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $179-$229/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the most common injection site for NAD+ therapy?

The abdominal area (2 inches from navel) is most common for subcutaneous NAD+ injection due to larger fat layer and easier self-administration. Rotating to thigh and upper arm sites every 1-2 weeks prevents tissue damage and maintains consistent absorption.

How deep should I inject NAD+?